486 related articles for article (PubMed ID: 16983109)
1. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M
J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
[TBL] [Abstract][Full Text] [Related]
3. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
[TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
6. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Chinot OL; Barrié M; Fuentes S; Eudes N; Lancelot S; Metellus P; Muracciole X; Braguer D; Ouafik L; Martin PM; Dufour H; Figarella-Branger D
J Clin Oncol; 2007 Apr; 25(12):1470-5. PubMed ID: 17442989
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.
Glas M; Happold C; Rieger J; Wiewrodt D; Bähr O; Steinbach JP; Wick W; Kortmann RD; Reifenberger G; Weller M; Herrlinger U
J Clin Oncol; 2009 Mar; 27(8):1257-61. PubMed ID: 19188676
[TBL] [Abstract][Full Text] [Related]
9. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Motomura K; Natsume A; Kishida Y; Higashi H; Kondo Y; Nakasu Y; Abe T; Namba H; Wakai K; Wakabayashi T
Cancer; 2011 Apr; 117(8):1721-30. PubMed ID: 21472719
[TBL] [Abstract][Full Text] [Related]
10. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
11. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
13. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
14. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
[TBL] [Abstract][Full Text] [Related]
15. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
[TBL] [Abstract][Full Text] [Related]
16. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Herrlinger U; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Maciaczyk J; Grau S; Schnell O; Hänel M; Krex D; Vajkoczy P; Gerlach R; Kortmann RD; Mehdorn M; Tüttenberg J; Mayer-Steinacker R; Fietkau R; Brehmer S; Mack F; Stuplich M; Kebir S; Kohnen R; Dunkl E; Leutgeb B; Proescholdt M; Pietsch T; Urbach H; Belka C; Stummer W; Glas M
J Clin Oncol; 2016 May; 34(14):1611-9. PubMed ID: 26976423
[TBL] [Abstract][Full Text] [Related]
20. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
